ANTI Stock Overview
Antigenics, Inc., a clinical-stage biopharmaceutical company, discovers, manufactures, and develops immunotherapies for cancer.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Antigenics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000007 |
52 Week High | US$0.000007 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -99.97% |
5 Year Change | n/a |
Change since IPO | -99.99% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
ANTI | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 1.0% | 1.2% |
1Y | n/a | 0.7% | 24.9% |
Return vs Industry: Insufficient data to determine how ANTI performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ANTI performed against the US Market.
Price Volatility
ANTI volatility | |
---|---|
ANTI Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ANTI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ANTI's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | n/a | n/a | agenusbio.com |
Antigenics, Inc., a clinical-stage biopharmaceutical company, discovers, manufactures, and develops immunotherapies for cancer. The company was founded in 1994 and is based in Lexington, Massachusetts.
Antigenics, Inc. Fundamentals Summary
ANTI fundamental statistics | |
---|---|
Market cap | US$320.00 |
Earnings (TTM) | US$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs ANTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ANTI income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$0 |
Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did ANTI perform over the long term?
See historical performance and comparison